Athersys (NASDAQ:ATHX) and University Hospitals Cleveland Medical Center (UH Cleveland) announce
that latter is now open as the first clinical site for the MACOVIA
(MultiStem Administration for COVID-19 Induced Acute Respiratory
Distress Syndrome) trial.
UH Cleveland has commenced enrollment and is now screening COVID-19 induced ARDS patients for inclusion in the trial.
The MACOVIA trial aims to confirm the safety and
efficacy of MultiStem therapy as a treatment for patients with moderate
to severe ARDS due to COVID-19.
The primary efficacy endpoint will be number of
ventilator-free days through day 28 as compared to placebo, and the
secondary objectives are to evaluate time in the intensive care unit,
pulmonary function, all-cause mortality and quality of life among
survivors.
The study is designed to enroll ~400 subjects.
https://seekingalpha.com/news/3567504-athersys-advances-multistem-study-in-covidminus-19-shares-up-14-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.